June 22, 2020 / 6:04 AM / 2 months ago

BRIEF-Evelo Biosciences Announces EDP1815 To Advance Into Phase 2/3 Tactic-E COVID-19 Trial

June 22 (Reuters) - Evelo Biosciences Inc:

* EVELO BIOSCIENCES ANNOUNCES EDP1815 TO ADVANCE INTO PHASE 2/3 TACTIC-E COVID-19 TRIAL

* INTERIM DATA EXPECTED IN Q4 OF 2020

* PHASE 2/3 PLATFORM TRIAL SPONSORED BY CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

* EDP1815 HAS BEEN OBSERVED TO HAVE FAVORABLE TOLERABILITY AND ANTI-INFLAMMATORY ACTIVITY IN A PRIOR CLINICAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below